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Abstract
Background: Omega-3 fatty acids (FAs) have been suggested as a beneficial supplement in chronic kidney disease
(CKD) patients, but the results of randomized clinical trials (RCTs) are controversial. We conducted a systematic review
and meta-analysis to evaluate all the RCTs about the impact of omega-3 FAs supplementation on cardiometabolic
outcomes and oxidative stress parameters in patients with CKD.
Methods: We performed a systematic database search in PubMed/MEDLINE, EMBASE, Scopus, Web of Science, and
Cochrane Central, up to May 2020. We included all placebo-controlled randomized trials that assessed the effect of
omega-3 FAs supplementation on any cardiometabolic outcomes: blood pressure, total cholesterol (TC), low-density
lipoprotein (LDL) and high-density lipoprotein (HDL) or triglycerides (TG) and oxidative stress parameters. Data were
pooled using DerSimonian–Laird’s random-effects model.
Results: Finally, thirteen articles met the inclusion criteria for this review omega-3 FAs supplementation significantly
decrease TC (SMD: -0.26; 95% CI: − 0.51, − 0.02; I2 = 52.7%), TG (SMD: -0.22; 95% CI: − 0.43, − 0.02; I2 = 36.0%) and
Malondialdehyde (MDA) levels (SMD: -0.91; 95% CI: − 1.29, − 0.54; I2 = 00.0%) and also significantly increase
superoxide dismutase (SOD) (SMD: 0.58; 95% CI: 0.27, 0.90; I2 = 00.0%) and Glutathione peroxidase (GPx) (SMD: 0.50;
95% CI: 0.14, 0.86; I2 = 00.0%) activities. However our results show that omega-3 FAs supplementation have no
significant effects on HDL, LDL and blood pressure.
Conclusion
This systematic review and meta-analysis supports current evidence for the clinical benefit of omega-3 FAs intake to
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improve cardiometabolic parameters in CKD patients. However, well-designed RCTs still needed to provide a
conclusive picture in this field.
Keywords: Cardio-metabolic outcomes, CKD, Omega-3 FAs, Oxidative stress, Blood lipids
Highlights
 Chronic kidney disease (CKD) is the progressive loss
of renal function that recognized as a global public
health problem
 Omega-3 fatty acids (FAs) have beneficial
supplement in chronic kidney disease (CKD)
patientssss
 Omega-3 FAs intake significantly improves lipid
profile and increases antioxidant defense enzymes in
CKD patients.
Background
Long-chain Omega-3 fatty acids such as, docosahexae-
noic acid (DHA) and eicosapentaenoic acid (EPA), are
polyunsaturated fatty acids that mostly intake from sea-
food [1, 2]. Omega-3 fatty acids (FAs) are widely used to
manage disease and complications [3]. Omega-3 FAs be-
cause of antioxidant properties can protect the cardio-
vascular system from oxidative stress and thrombotic
complications [4].
Patients with chronic kidney diseases (CKD) who
are maintained with dialysis or nephropathy have a
risk of coronary heart disease, myocardial infarction,
and atherosclerosis [5, 6]. Cardiometabolic factors
such as hypertension, dyslipidemia, hyperglycemia,
and obesity are determinant risk factors in the general
population [7, 8]. Cardiometabolic risk factors impose
a great burden on health and insurance systems all
over the world [9, 10] and they are even more harm-
ful in people with underlying diseases such as CKD
[11–13]. Elevated levels of low-density lipoprotein
(LDL), accumulate remnant lipoproteins as well as ox-
idized LDL (ox-LDL) and generate atherosclerosis
[14]. Patients, undergoing hemodialysis, are at higher
risk due to metabolic changes, increased lipid profile
can result in unpleasant disorders that must be pre-
vented [15]. However, lipid profile especially TC levels
considered as nutritional parameters [16], which have
been demonstrated to be strictly related to cardiomet-
abolic risks in CKD patients [17].
Patients with end-stage renal disease (ESRD) do not
receive enough omega-3 fatty acids due to limited con-
sumption of rich food of omega-3 fatty acids, such as
nuts and fishes [18]. Some of the RCTs indicated the ad-
ministration of n-3 fatty acids has a beneficial effect on
serum lipid profile, but maybe depending on the selected
dose [19]. Recent randomized controlled trials (RCTs)
show omega-3 supplements (EPA and DHA) usually
have opposite effects versus placebo [18, 20].
Previous clinical trials have examined the effect of
omega-3 supplements on cardiometabolic factors that
have been performed in patients with CKD, but no
meta-analysis and systematic review reported the overall
impact of n-3 PUFA clinical trials. Thus, our study
aimed to evaluate the overall effects of oral omega-3
supplementation on serum lipid profile, hypertension
and antioxidant markers in CKD patients.
Methods
Search strategy
This meta-analysis was performed according to the PRIS
MA guidelines [21]. Electronic databases, including
PubMed/MEDLINE, EMBASE, Scopus, ISI Web of Sci-
ence, and Cochrane Central, were systematically
searched up to May 2020. The search strategy was con-
ducted without any language or time restriction. Mesh
terms were used to PubMed and topic heading titles
were used for other databases search. The systematic
search was completed using the following terms: Fish
Oil OR Fatty Acids, Omega-3 OR Docosahexaenoic
Acids OR “DHA” OR Eicosapentaenoic Acid OR “EPA”
OR Timnodonic Acid AND Dialysis OR Hemodialysis
OR Peritoneal dialysis OR Kidney disease OR Chronic
kidney disease OR End stage renal disease OR Chronic
renal failure AND Randomized controlled trial OR con-
trolled clinical trial OR randomized controlled trials.
Complete search terms and syntaxes are presented in
Additional file 1.
Study selection & quality appraisal
The titles and abstracts of the studies were screened by
two independent investigators (S.F and F.M), then the
full text of the related articles was checked, and any dis-
agreements were resolved by consensus. All human
clinical trials that reported the effect of omega-3 supple-
mentation on cardiometabolic factors in chronic kidney
patients were included in the current meta-analysis. Ex-
perimental studies, trials that used a combination of
omega-3 and other interventions and studies that used
olive oil or medium-chain triglyceride (MCT) as a pla-
cebo, were excluded. The primary outcomes of this re-
view were cardiometabolic factors such as blood lipids
(TC, TG, LDL and HDL), and systolic or diastolic blood
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pressure. The secondary outcomes were oxidative stress
parameters (TAC, MDA, SOD and Gpx activity). We
evaluated the methodological quality of each included
trial using criteria from the Cochrane Collaboration
guidelines [22].
Data extraction and data analysis
The review of primary studies was performed by one au-
thor (S.F) and then the data were double-checked by a
second one (F.M) and any discrepancies were discussed
by the other author (J.H), we extracted general charac-
teristics of the study include of first author’s name, year
of publication, country, subjects, sample size, mean age,
gender, dose and type of supplemented omega-3 and
main outcomes that has been indicated in Table 1. The
mean and standard deviation of the primary outcomes
associated with cardiometabolic were extracted from re-
lated articles for continuous and binary data we calcu-
lated the standardized mean difference (SMD). Standard
Errors (SE), confidence interval, interquartile range
(IQR), and minimum-maximum value of each cardio-
metabolic marker in omega-3 and placebo group were
converted to Standard Deviations (SD).
All statistical analysis was performed with a random
effect model based on the Inverse-Variance method
using STATA software version 13 (STATA Corp,
College Station, Texas). We assessed the heterogeneity
of studies using heterogeneity chi-squared tests with a
P-value of less than 0.1 and I2 statistic more than 50%
considered as significant heterogeneity [22]. Subgroup
analysis based on duration and dose of omega-3 FAs
supplementation was conducted. The funnel plot, Begg
and Egger test were used to evaluate the publication bias
of included trials [36]. Sensitivity analysis was performed
to assess the extent to which inferences might depend
on an individual trial.
Results
Search results
The study identification and study selection process is
presented in the PRISMA flow diagram in Fig. 1. Initial
database search yielded an aggregate of 1405 potentially
relevant records. After reading the title and abstract of
duplicate removed records, 36 studies remained for the
comprehensive full-text evaluations. Of these 36 articles,
23 more studies were excluded for various reasons.
Finally, 13 articles [23–35] met the inclusion criteria for
this review.
Study characteristics
The main characteristics of the included articles are
presented in Table 1. All the included studies were
published between 1994 and 2017. The included trials
originated from the Iran (n = 7), the United States (n =
1), Egypt (n = 1), Algeria (n = 1), Japan (n = 1), Sweden
(n = 1), and Greece (n = 1). The total number of partici-
pants in all included trials was 708. Ten studies evalu-
ated the effect of omega-3 FAs on hemodialysis patients
[23, 24, 27–31, 33–35], two IgA nephropathy patients
[26, 32] and one in chronic renal failure patients [25].
The duration of omega-3 supplementation in studies
ranged from 8 to 192 weeks. The mean age of partici-
pants in included studies ranged from 14.1 to 64 years
old. Among the 13 included studies, one used EPA-only
supplements [23], and the other 12 trials involved sup-
plementation of EPA/DHA combinations. Omega-3 FAs
dosage ranged from 1000 to 6000 mg/day in trials.
Risk of bias assessment
The risk of bias evaluation of included studies is shown
in Additional file 2. Overall, seven trials reported on ran-
dom sequence generation [26–28, 30, 31, 33, 34], seven
reported precise and correct allocation concealment [23,
24, 27, 30, 31, 33, 34]. Five trials were evaluated as hav-
ing a high risk of performance bias [23, 26, 28, 29, 35]
and only two studies have evaluated as have a low detec-
tion bias [25, 31]. Three studies were considered to have
attrition bias [25, 30, 32] and the risk of selective report-
ing was high in two trials [23, 32].
Blood pressure
Two included studies evaluated the effects of omega-3
FAs supplementation on blood pressure in CKD pa-
tients. The results of meta-analysis show that omega-3
FAs supplementation have no effect on SBP (SMD:
-0.74; 95% CI: − 1.56, 0.07; I2 = 74.4%) (Fig. 2a) and DBP
(SMD: -0.33; 95% CI: − 1.36, 0.70; I2 = 84.3%) (Fig. 2b).
Blood lipids
Meta-analysis of 11 included trials show that omega-3
FAs supplementation significantly reduce TC levels in
CKD patients (SMD: -0.26; 95% CI: − 0.51, − 0.02; I2 =
52.7%) (Fig. 3a). Subgroup analysis based on duration
did not show any significant changes (Table. 2), but sub-
group analysis based on the dose of omega-3 FAs sup-
plementation shows that omega-3 FAs supplementation
is less or equal to 2000mg/day significantly decrease TC
levels (Table. 2). Meta-analysis of 12 included studies
demonstrated that omega-3 FAs supplementation sig-
nificantly reduce TG levels in CKD patients (SMD:
-0.22; 95% CI: − 0.43, − 0.02; I2 = 36.0%) (Fig. 3b). strati-
fication of results according to the duration of omega-3
FAs supplementation indicates that TG decreased
significantly in more than 10 weeks of omega-3 FAs
supplementation (SMD: -0.36; 95% CI: − 0.63, − 0.10;
I2 = 38.3%) (Table. 2). According to omega-3 FAs doses,
subgroup analysis did not show any significant changes
(Table. 2). Meta-analysis on ten studies that evaluated
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the effect of omega-3 FAs on HDL in CKD patients did
not show significant changes (SMD: -0.12; 95% CI: −
0.60, 0.36; I2 = 87.0%) (Fig. 3c). stratification based on
omega-3 FAs intake duration indicated that omega-3
FAs decreased HDL levels in more than 10 weeks of dur-
ation in CKD patients (SMD: -0.49; 95% CI: − 0.90, −
Table 1 Main characteristics of included studies
Study (year) Country Subjects Sample
size
























































Iran HD 117 3000 – 12 75/25 61.05 ±
17.42
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57.76 ± 15.56 ↑HDL, ↔LDL,
↔TC,
↔TG
Naini et al [31]
(2015)






























Iran HD 75 3000 540 360 – 8 49/26 49.3 ± 1.8 48.8 ± 2.7 ↑GPX, ↓MDA,
↑SOD,
a Hemodialysis, bChronic Renal Failure, c Total cholesterol, d Triglyceride, e High-density lipoprotein, f low-density lipoprotein, g Malondialdehyde, h Glutathione
peroxidase, i Superoxide dismutase, j diastolic blood pressure, k Systolic blood pressure, l peritoneal dialysis
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0.09; I2 = 71.8%) (Table. 2) compare to less and equal
than 10 weeks (SMD: 0.83; 95% CI: − 0.32, 1.97; I2 =
92.6%). Subgroup analysis based on omega-3 FAs doses
did not show any significant changes (Table. 2). Nine tri-
als evaluated the effect of omega-3 FAs on LDL levels in
CKD patients. Meta-analysis indicated that effect
omega-3 FAs supplementation did not have significant
effects on LDL levels (SMD: -0.10; 95% CI: − 0.27, 0.07;
I2 = 00.0%) (Fig. 3d). Subgroup analysis based on dur-
ation and dose of omega-3 FAs supplementation did not
show any significant changes in this effect (Table 2).
Oxidative stress
The result of our meta-analysis indicated that omega-3
FAs supplementation significantly increase GPx (SMD:
0.50; 95% CI: 0.14, 0.86; I2 = 00.0%) (Fig. 4a), and SOD
activities (SMD: 0.58; 95% CI: 0.27, 0.90; I2 = 00.0%)
(Fig. 4b), and also significantly decrease MDA levels
(SMD: -0.91; 95% CI: − 1.29, − 0.54; I2 = 00.0%) (Fig. 4c)
in CKD patients.
Sensitivity analysis and publication bias assessment
The main outcomes of the meta-analysis did not alter
after drop out of any single of the included trials except
for the condition as follow: The significant finding of the
meta-analysis of the effect omega-3 FAs supplementa-
tion on TC altered to “insignificant” after drop out of
the dataset of Ateya et al. [24] According to Begg and
Egger test there was no publication bias in our results.
Findings of the funnel plots are presented in Additional
file 3.
Discussion
This systematic review and meta-analysis investigated
the efficacy of omega-3 FAs supplementation on cardio-
metabolic outcomes and oxidative stress parameters in
patients with CKD. Our results indicated that omega-3
FAs supplementation significantly reduces TC, TG, and
MDA levels and substantially increases SOD and GPx
activity. However, our results show that omega-3 FAs in-
take has no significant effects on HDL, LDL and blood
pressure. Several systematic reviews evaluated the effects
of omega-3 FAs intake on CKD patients. It should be
noted that CKD is a very heterogeneous disease. IgA ne-
phropathy, CKD, and HD patients are collectively re-
ferred to as CKD patients, but the significance of
improving lipids, blood pressure, and oxidative stress
markers differ depending on the pathology, so due to
Fig. 1 PRISMA Flow diagram of study selection
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great heterogeneity current results should be declared
with caution.
In line with our results, Saglimbene et al. in 2020 [37]
demonstrated that omega-3 FAs intake might decrease
cardiovascular mortality in hemodialysis patients, but it
is uncertain whether omega-3 FAs intake reduces the
risk of mortality or ESKD in subjects with CKD. Wu
et al. [38] also indicated that omega-3 FAs supplementa-
tion might improve inflammatory factors in dialysis pa-
tients. In previous systematic reviews, omega-3 FAs
intake has beneficial effects on the Lipid profile of CKD
patients [39, 40].
Our results indicated that omega-3 FAs intake did not
have a significant impact on systolic and dyastolic blood
pressure in patients with CKD. However, the small num-
ber of included studies that evaluated the effect of
omega-3 FAs intake on blood pressure in CKD patients
makes it difficult for us to find a possible significant ef-
fect. In addition, significant reduction was observed just
in Naini et al. [31] which is conducted on PD patients,
so maybe this effect is related to the specific pathophysi-
ology of PD patients. There are several studies that dem-
onstrated the beneficial effect of omega-3 FAs
supplementation on improvement of blood pressure [41,
Fig. 2 Forest plot of the effect of omega-3 FAs supplementation on SBP (a) and DBP (b) in CKD patients
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42], so maybe if there were more RCTs, we could find a
significant effect of omega-3 FAs intake on blood pres-
sure in CKD patients.
Our results indicated that omega-3 FAs intake has no
effect on HDL levels in CKD patients. However, the sub-
group analysis based on duration showed that omega-3
FAs intake more than ten weeks of duration significantly
decrease HDL levels. This result is in contrast with Zho
et al. [40] that shows that omega-3 FAs intake signifi-
cantly increases HDL levels in dialysis patients. Several
reasons could be proposed for these different results be-
tween present the review, and Zho et al. various in-
cluded studies may cause the primary reason for these
discrepancies in results. In this field, Eslick et al. [39] in-
dicated that fish oil intake may slightly (non-signifi-
cantly) increase HDL levels. Our results also showed
that omega-3 FAs intake has no effect on LDL levels in
CKD patients. Nevertheless, we observed a non-
significant decrease in LDL levels, and maybe if there
were more trials, we could find this reduction significant.
Because previous reviews also endorse that omega-3 FAs
supplementation can be useful in improving LDL levels
[43, 44]. Our meta-analysis results indicated that omega-
3 FAs intake significantly decreases TC levels in patients
with CKD. This outcome is in accordance with Zhu
et al. [40] results. Several mechanisms could be proposed
for the effect of omega-3 FAs intake on TC levels. It has
been shown that omega-3 FAs can reduce cholesterol
levels via suppression of endogenous cholesterol synthe-
sis [45]. Actually, it has been suggested that omega-3
FAs intake caused a significant decrease in the mRNA
expression levels of 3-Hydroxy-3-Methyl-Glutaryl-Coen-
zyme A reductase (HMG-CoA reductase) which is the
limited rate enzyme in cholesterol synthesis [46]. Re-
cently it has been shown that cholesterol metabolism
also is regulated by microRNA regulation [47]. micro-
RNAs (miRNAs) are small non-coding RNAs that play
important roles in posttranscriptional gene regulation
[48, 49]. Several studies have been demonstrated that
omega-3 fatty acid regulates cholesterol metabolism
through modulation of different miRNAs [50]. So maybe
the effect of omega-3 supplementation on cholesterol re-
lated to the regulation of miRNAs. In the present study,
subgroup analysis based on omega-3 FAs dose indicated
that omega-3 FAs intake less than 2000 mg/day is more
efficient to reduce TC levels compare to more than
2000 mg/day.
Our results also indicated that omega-3 FAs intake
significantly reduces TG levels. This result is following
previous findings that demonstrate the beneficial effects
of omega-3 FAs intake on TG levels [51–53]. Our results
also show that omega-3 FAs intake reduces TG more ef-
ficiently in more than ten weeks of duration compare to
less or equal to 10 weeks. Omega-3 FAs may represent
Fig. 3 Forest plot of the effect of omega-3 FAs supplementation on
TC (a) TG (b), HDL (c) and LDL (d) in CKD patients
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their hypotriglyceridemic impacts by several possible
mechanisms. It has been demonstrated that omega-3
FAs can affect the genetic or epigenetic factors and re-
lated regulatory proteins [54–57], for instance, omega-3
FAs may inhibiting hepatic lipogenesis via decreasing
levels of sterol receptor element-binding protein–1c
(SREBP-1c), the leading genetic switch controlling lipo-
genesis [58, 59]. Omega-3 FAs have been shown to in-
hibit SREBP-1c transcription through a diminished
trans-activating capacity of Liver X receptor alpha
(LXRα) [60]. Besides it has been suggested that omega-3
FAs intake upregulates fatty acids oxidation in the skel-
etal muscle and liver via activation of Peroxisome
proliferator-activated receptor (PPARs) [61, 62], and in-
creasing flux of glucose to glycogen via suppression of
hepatocyte nuclear factor–4α (HNF-4α) [63, 64]. The
net outcome is the change in the source of metabolic
fuel from storage TG toward oxidation.
Our results show that omega-3 FAs intake improves
the antioxidant defense system through increase GPx
and SOD activity and decrease MDA concentrations.
However the number of included studies that evaluated
the effect of omega-3 FAs supplementation on oxidative
stress parameters in CKD patients was very limited, so
this result should be declared with caution. The antioxi-
dant effect of omega-3 FAs supplementation in improv-
ing oxidative stress parameters has been demonstrated
in previous systematic reviews [65–67]. Oxidative stress
is a pivotal contributor to cardiometabolic risk factors in
CKD patients [68]. Therefore, reduces cell toxicity
related to increasing apoptosis and cell death through
regulation of oxidative stress is very critical to cell sur-
vival [69]. Mitochondrial biogenesis is strictly related to
oxidative stress and cell survival [70]. SOD activity also
is related to mitochondrial biogenesis [71]. In this re-
gard, it has been shown that omega-3 FAs intake regu-
lates mitochondrial biogenesis through increase SOD
activity [72]. In addition to the effect of omega-3 on oxi-
dative stress, it has been shown that omega-3 fatty acids
have a strenght immunomodulatory effect which can
affect antioxidant enzymes and lipid peroxidation pa-
rameters such as GPx and MDA [73]. Eicosanoids gener-
ated from arachidonic acid have critical roles in the
regulation of the immune system [74]. Omega-3 fatty
acids such as EPA and DHA produced different eicosa-
noids; these may have different functions to arachidonic
acid-derived ones especially in the brain [75] and kid-
neys [76]. Human immune cells generally have a great
amount of arachidonic acid, but arachidonic acid, DHA,
and EPA amount of cells can be changed via oral intake
of those fatty acids. It has been demonstrated that
omega-3 FAs eicosanoids are more resistant to lipid per-
oxidation and decrease MDA levels [77].
Strengths and limitations
Our systematic review has evaluated the impacts of
omega-3 FAs intake on CKD patients. Our database
search was without language restrictions and very com-
prehensive. We also assessed the quality of the included
trials. We investigated the impacts of different factors
Table 2 Subgroup analysis assessing the effect of omega-3 FAs supplementation on metabolic parameters in CKD patients
Variable Sub-grouped by No. of arms effect size (SMD) 95% CI I2 (%) P for heterogeneity
TC Duration > 10 weeks 8 −0.31 − 0.66, 0.03 64.1 0.007
≤10 weeks 3 −0.14 − 0.41, 0.13 00.0 0.540
omega-3 FAs dosage ≤ 2000 mg/day 5 −0.61 −1.07, − 0.14a 58.9 0.045
> 2000 mg/day 6 −0.04 −0.23, − 0.15 00.0 0.961
TG Duration > 10 weeks 8 −0.36 −0.63, − 0.10a 38.3 0.125
≤10 weeks 3 0.03 −0.23, 0.29 00.0 0.692
omega-3 FAs dosage ≤ 2000 mg/day 5 −0.36 − 0.74, 0.02 40.5 0.151
> 2000 mg/day 7 −0.12 −0.35, 0.10 23.7 0.249
HDL Duration > 10 weeks 7 −0.49 −0.90, − 0.09a 71.8 0.002
≤10 weeks 3 0.83 −0.32, 1.97 92.6 0.000
omega-3 FAs dosage ≤ 2000 mg/day 5 0.04 −0.97, 1.06 93.0 0.000
> 2000 mg/day 5 −0.18 − 0.53, 0.17 55.2 0.063
LDL Duration > 10 weeks 6 −0.06 −0.27, 0.16 00.0 0.513
≤10 weeks 3 −0.17 −0.44, 0.10 00.0 0.948
omega-3 FAs dosage ≤ 2000 mg/day 4 −0.10 −0.40, 1.20 22.0 0.278
> 2000 mg/day 5 −0.13 −0.35, 0.10 00.0 0.937
SMD Standard mean difference, CI confidence interval. TC Total cholesterol, TG Triglyceride, HDL High density lipoprotein, LDL Low density lipoprotein
astatistically significant
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Fig. 4 Forest plot of the effect of omega-3 FAs supplementation on oxidative stress parameters; GPx(a), SOD (b) and MDA (c)
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including properties of the participants and treatment
on the effects of the supplements. The included trials
are very varied in the type of omega-3 FAs, dose and
duration of administration. Besides, there is limited re-
ported data about the compliance of intervention in par-
ticipants. Moreover, even with contacting the authors,
we could not get enough information in some of the in-
cluded studies. Given the limited number of trials in
each subgroup analysis, we could not conduct a meta-
regression analysis. In addition, the evaluation the risk of
CVD disease in CKD patients in different stages may not
a good way to conclude the effect of omega-3 FAs inter-
vention on cardio-metabolic risk factors in CKD pa-
tients. It is well established that the pathogenesis of
cardio-metabolic parameters is different in HD patients
and non-dialysis CKD patients. Therefore, the impact of
fatty acids intervention on hard outcomes is thought to
vary by CKD stage and there are controversial results in
the literature. For example, it has been shown that the
higher the TC and TG levels are associated with, the
higher the risk of developing coronary artery disease in
CKD patients [78], but interventions to reduce blood
lipids indicated that these treatments are effective for de-
crease total mortality and CVD events in early CKD
stages, but have little benefit in dialysis patients [79] or
even did not significantly improve CVD-related hard
endpoints when limited to hemodialysis patients [80].
Moreover of thirteen included studies, ten of them were
performed on HD patients so the majority of results
may be related to HD patients. In addition, significant
heterogeneity was encountered perhaps due to various
settings, populations enrolled etc., calling for cautious
interpretation of the results. Also, the effect in many var-
iables such as blood pressure was evaluated by very few
included trials and the effect may related to a specific
disease condition like PD patients; thus, the evidence to
support it is low. Finally, the vast majority of included
trials originated from Iran; thus, extrapolation of these
results to Western should be considered with caution.
Conclusion
This systematic review and meta-analysis support
current evidence for a clinical benefit of omega-3 FAs
intake to improve cardiometabolic parameters in CKD
patients. These results show that omega-3 FAs intake
significantly decrease TC, TG and MDA levels and also
considerably increases SOD and GPx activity. However
well-designed large randomized clinical trials still needed
to provide a conclusive picture of the effect of omega-3
FAs supplementation on oxidative stress and blood pres-
sure parameters in patients with CKD.
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